ABT - Abbott Laboratories

NYSE - Nasdaq Real Time Price. Currency in USD
-0.58 (-0.73%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close79.96
Bid79.24 x 800
Ask79.25 x 800
Day's Range79.11 - 80.02
52 Week Range56.81 - 80.25
Avg. Volume6,668,288
Market Cap139.429B
Beta (3Y Monthly)0.90
PE Ratio (TTM)59.73
EPS (TTM)1.33
Earnings DateApr 17, 2019
Forward Dividend & Yield1.28 (1.62%)
Ex-Dividend Date2019-04-12
1y Target Est80.55
Trade prices are not sourced from all markets
  • Medtronic (MDT) Releases Encouraging Evalut TAVR Result
    Zacks2 hours ago

    Medtronic (MDT) Releases Encouraging Evalut TAVR Result

    Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

  • Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms
    Zacks3 hours ago

    Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms

    Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.

  • Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
    Zacks4 hours ago

    Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

    Is (ABT) Outperforming Other Medical Stocks This Year?

  • PR Newswire4 hours ago

    Abbott Hosts Conference Call for First-Quarter Earnings

    ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019 , before the market opens.  The announcement will ...

  • Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised)
    Zacks5 hours ago

    Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised)

    The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional MR.

  • What Makes Abbott (ABT) a New Buy Stock

    What Makes Abbott (ABT) a New Buy Stock

    Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Why You Should Buy ABBV Stock for Income and Value

    Why You Should Buy ABBV Stock for Income and Value

    Today, I'd like to discuss the outlook for AbbVie (NYSE:ABBV), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25.Source: Shutterstock * Top 7 Service Sector Stocks That Will Pay You to Own Them There could be further price volatility and weakness in the ABBV stock price in the coming weeks, pushing it toward the low-$70's or even mid-$60's level. However, it is a company with robust growth prospects and respectable dividends that may deserve a place in a diversified portfolio.Therefore, if you already own AbbVie shares, you might want to hold your position. That said, within the parameters of your portfolio allocation and risk/return profile, you may consider placing a stop loss at about 5-7% below the current price point. Expect nearer-term trading to be choppy at best.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf you are an experienced investor in the options market, you may want to protect your portfolio with a covered call or possibly a put option spread with a 3-month time horizon. If you do not yet hold ABBV, you may want to wait several weeks to buy into the stock at the next dip.With all of that in mind, here's a deeper look into at AbbVie stock. A Hiccup in the Robust Fundamental StoryIn 2013, Abbott Laboratories (NYSE:ABT) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. Abbott decided to retain the branded generic pharmaceuticals, diagnostics, medical devices and nutrition.Meanwhile, AbbVie took control of the development and commercialization of a range of brands, including Humira, its flagship drug used to treat autoimmune diseases, Imbruvica, which differentiates between cancer cells and regular cells, and Synthroid, a replacement for a hormone normally produced by the thyroid gland.The company's financials and growth metrics over the past five years have been impressive and ABBV was in a strong financial position heading into 2019, with hopes of a higher share price during the first quarter.However, in January, AbbVie's fourth-quarter earnings release weighed heavily on the stock. For starters, the company missed the consensus on revenue. Its earnings per share of $1.90 was below the expected number of $1.94. The next day, the stock fell by 6% and that decline has intensified over the past two months.ABBV's quarterly report also showed that the international sales of Humira fell by almost 15% year over year, mostly as a result of 'biosimilar' competition in Europe, which makes up three-quarters of the overseas Humira business. In October 2018, its patent in the European Union (E.U) expired.The U.S. Food and Drug Administration (FDA) refers to biosimilars as "highly similar to an FDA-approved biological product … [that has] no clinically meaningful differences in terms of safety and effectiveness." Although Wall Street had already known about this sales decline in Europe, when coupled with the other question marks in the earnings report, it was enough to increase the selling pressure on the stock.It is also possible that investors got worried about the potential fall in Humira revenue when the drug comes off patent in 2023 in the U.S. It is important to emphasize that AbbVie's revenue from the drug will not decline to nothing when the biosimilars hit the market in 2023. What will most likely happen is that as the company's pricing power decreases, the revenue will also gradually decline.Therefore, many analysts feel that ABBV shares offer value and that any bad news that is specific to Humira is already baked into the stock price. Value PlayWhen markets penalize biopharma stocks, it can take some time for them to recover. However, for patient long-term investors, the returns can be significant -- especially when the company boasts several other current drugs, as well promising ones in the pipeline.At present, AbbVie's other major products include: * AndroGel, a testosterone replacement therapy. * Creon, a pancreatic enzyme therapy to treat exocrine pancreatic insufficiency. * Duopa and Duodopa, gels to treat Parkinson's disease. * Viekira Pak, which treats chronic hepatitis C. * Zinbryta, to treat multiple sclerosis.Analysts are also expecting a slew of new products in 2020, such as next-generation immunology drugs. These drugs and others that are being developed and commercialized, highlight how impressive the potential growth story could be in the next few years.ABBV trades at a trailing price-to-earnings (P/E) ratio of 21. This number is rather modest when compared with the P/E ratios of several competitors, including AstraZeneca (NYSE:AZN) with a P/E of 49.9, Pfizer (NYSE:PFE) with a P/E of 25.2, and Merck (NYSE:MRK) with a P/E of 34.8. Reinvesting the Sweet Dividend Yield of ABBV stockIncome investors know that they can compound their returns through reinvesting dividends from high-yielding shares. AbbVie also offers investors a healthy dividend yield of about 5.4%, another reason why I believe the stock belongs in a capital-growth portfolio.Since its spin-off from Abbott Laboratories in 2013, ABBV has increased dividends every year -- a trend that is likely to continue. The next dividend payment is scheduled for May 15, 2019, with an ex-dividend date of April 12.It would not be wrong to call AbbVie a cashflow machine; as of Dec. 31, the company had a free cash flow of $3.27 billion. This strength not only gives shareholders conviction that the dividends are safe, but also provides the company with enough flexibility to, for example, make acquisitions to offset any further Humira revenue decline (especially in the U.S. when the drug comes off patent in 2023). The Bottom Line on AbbVie StockLike most biopharma stocks, AbbVie is a high-momentum stock. In other words, when the broader markets go up or when the company's earnings beat expectations, both investors and momentum traders tend to hit the "buy" button fast, expecting superior gains within days or weeks.However, if markets suffer a decline or if the company cannot keep up with the rising expectations, investors' risk appetite decreases fast and these stocks can fall much harder than less volatile stocks. * 7 Financial Stocks to Invest In Today The market has punished Abbvie stock since the start of the year. The stock may continue to struggle through much of 2019. However, patient ABBV bulls will probably be proven right to believe in the management's commitment to create shareholder value and to further grow the company both organically and through acquisitions. In the meantime, they can continue to collect high dividends.As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise Compare Brokers The post Why You Should Buy ABBV Stock for Income and Value appeared first on InvestorPlace.

  • PR Newswireyesterday

    Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

    This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests.

  • 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?
    Motley Foolyesterday

    3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

    Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

  • Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
    Zacks2 days ago

    Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

    Abbott (ABT) closed the most recent trading day at $78.83, moving -1.29% from the previous trading session.

  • PR Newswire3 days ago

    New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump

    NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint of event free survival while showcasing improved rates of overall survival, quality of life and a reduction in adverse events with the HeartMate 3™ left ventricular assist device (LVAD).

  • PR Newswire3 days ago

    New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device

    NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (ABT) today announced positive late-breaking data from two separate analyses of the COAPT™ Trial showing additional key benefits from treatment with MitraClip™ for heart failure patients with clinically significant secondary (or functional) mitral regurgitation (MR), or leaky heart valve. Both data sets were presented today at the American College of Cardiology's (ACC) 68th Annual Scientific Session.

  • Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip
    Zacks5 days ago

    Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip

    The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.

  • Abbott Stock Isn't Heartbroken As FDA Approves New Valve Implant
    Investor's Business Daily6 days ago

    Abbott Stock Isn't Heartbroken As FDA Approves New Valve Implant

    Abbott Laboratories stock closed at a record high Thursday after the Food and Drug Administration approved a new use for its implant, MitraClip, in functional mitral regurgitation.

  • PR Newswire6 days ago

    Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device

    ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

  • FDA medical adviser: 'Congress is owned by pharma'
    Yahoo Finance7 days ago

    FDA medical adviser: 'Congress is owned by pharma'

    Despite many politicians, particularly declared presidential candidates, beginning to speak out against big pharma, an FDA medical adviser does not think that anything will come out of it “because Congress is owned by pharma.”

  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks8 days ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ABT had net inflows of $3.76 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. ABT credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Better Buy: Abbott Laboratories vs. Johnson & Johnson
    Motley Fool10 days ago

    Better Buy: Abbott Laboratories vs. Johnson & Johnson

    Which stock wins in a matchup between these two healthcare giants?

  • Financial Times12 days ago

    [$$] Javid faces fresh row over Begum case after baby’s death

    , on Saturday faced mounting criticism from across the political spectrum over his handling of the case of Shamima Begum, the 19-year-old British woman who joined Islamic State, following the death of her baby on Friday. Mr Javid last month decided to strip Ms Begum of her UK citizenship after she announced that she wanted to return to Britain from Syria, to where she travelled four years ago to live in the territory of the violent Islamist group. , produced renewed criticism following the baby’s death because of its potential role in efforts to help the child, who remained a British citizen because he was born, before Mr Javid revoked his mother’s citizenship.

  • The World's Top 10 Health Care Companies (UNH, MDT)
    Investopedia13 days ago

    The World's Top 10 Health Care Companies (UNH, MDT)

    Discover the world's top 10 health care companies according to market capitalization, including a brief summary of each.

  • Top Analyst Reports for Boeing, Abbott & PayPal
    Zacks14 days ago

    Top Analyst Reports for Boeing, Abbott & PayPal

    Top Analyst Reports for Boeing, Abbott & PayPal

  • The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

    The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

  • PR Newswire14 days ago

    Late-Breaking Data Presentations at ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio

    - Five late-breaking data presentations at ACC 2019 showcase the breadth and depth of Abbott's cardiovascular portfolio - New late-breaking data highlight outcomes for key Abbott cardiovascular technologies: ...

  • ETF Trends16 days ago

    Healthcare ETF Keeps Hitting New Highs

    Just a dozen ETFs hit record highs on Friday. Extending its 2019 gains to 15%, the iShares US Medical Devices ETF (NYSEArca: IHI) was one of the ETFs hitting all-times on Friday. That as the broader healthcare ...